Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.01
TRIB's Cash to Debt is ranked lower than
64% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. TRIB: 1.01 )
Ranked among companies with meaningful Cash to Debt only.
TRIB' s 10-Year Cash to Debt Range
Min: 0.03  Med: 94.74 Max: No Debt
Current: 1.01
Equity to Asset 0.57
TRIB's Equity to Asset is ranked lower than
54% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TRIB: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
TRIB' s 10-Year Equity to Asset Range
Min: 0.29  Med: 0.75 Max: 0.88
Current: 0.57
0.29
0.88
Interest Coverage 261.43
TRIB's Interest Coverage is ranked lower than
52% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. TRIB: 261.43 )
Ranked among companies with meaningful Interest Coverage only.
TRIB' s 10-Year Interest Coverage Range
Min: 0.73  Med: 11.14 Max: 9999.99
Current: 261.43
0.73
9999.99
F-Score: 5
Z-Score: 3.13
WACC vs ROIC
5.03%
8.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 15.76
TRIB's Operating margin (%) is ranked higher than
87% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. TRIB: 15.76 )
Ranked among companies with meaningful Operating margin (%) only.
TRIB' s 10-Year Operating margin (%) Range
Min: -56.78  Med: 11.62 Max: 67.5
Current: 15.76
-56.78
67.5
Net-margin (%) 14.70
TRIB's Net-margin (%) is ranked higher than
90% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. TRIB: 14.70 )
Ranked among companies with meaningful Net-margin (%) only.
TRIB' s 10-Year Net-margin (%) Range
Min: -55.5  Med: 9.11 Max: 67.4
Current: 14.7
-55.5
67.4
ROE (%) 7.64
TRIB's ROE (%) is ranked higher than
67% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. TRIB: 7.64 )
Ranked among companies with meaningful ROE (%) only.
TRIB' s 10-Year ROE (%) Range
Min: -76.72  Med: 8.25 Max: 54.77
Current: 7.64
-76.72
54.77
ROA (%) 5.73
TRIB's ROA (%) is ranked higher than
75% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. TRIB: 5.73 )
Ranked among companies with meaningful ROA (%) only.
TRIB' s 10-Year ROA (%) Range
Min: -45.03  Med: 5.87 Max: 41.2
Current: 5.73
-45.03
41.2
ROC (Joel Greenblatt) (%) 28.92
TRIB's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. TRIB: 28.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TRIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -123.61  Med: 24.37 Max: 125.23
Current: 28.92
-123.61
125.23
Revenue Growth (3Y)(%) 8.00
TRIB's Revenue Growth (3Y)(%) is ranked higher than
62% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. TRIB: 8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TRIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -30.9  Med: -0.60 Max: 108.2
Current: 8
-30.9
108.2
EBITDA Growth (3Y)(%) 0.30
TRIB's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. TRIB: 0.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TRIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.8  Med: 1.60 Max: 125.1
Current: 0.3
-45.8
125.1
EPS Growth (3Y)(%) 1.40
TRIB's EPS Growth (3Y)(%) is ranked higher than
50% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. TRIB: 1.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TRIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.9  Med: -0.50 Max: 75.6
Current: 1.4
-52.9
75.6
» TRIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

TRIB Guru Trades in Q3 2014

Chuck Royce 265,000 sh (unchged)
Jim Simons 430,150 sh (-4.63%)
» More
Q4 2014

TRIB Guru Trades in Q4 2014

Zeke Ashton 135,000 sh (New)
Chuck Royce 365,792 sh (+38.03%)
Jim Simons 324,929 sh (-24.46%)
» More
Q1 2015

TRIB Guru Trades in Q1 2015

Chuck Royce 371,000 sh (+1.42%)
Zeke Ashton 135,000 sh (unchged)
Jim Simons 246,954 sh (-24.00%)
» More
Q2 2015

TRIB Guru Trades in Q2 2015

Chuck Royce 519,298 sh (+39.97%)
Jim Simons 268,363 sh (+8.67%)
Zeke Ashton 120,000 sh (-11.11%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 10.70
TRIB's P/E(ttm) is ranked higher than
99% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. TRIB: 10.70 )
Ranked among companies with meaningful P/E(ttm) only.
TRIB' s 10-Year P/E(ttm) Range
Min: 2.08  Med: 16.87 Max: 69.1
Current: 10.7
2.08
69.1
Forward P/E 29.15
TRIB's Forward P/E is ranked lower than
71% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. TRIB: 29.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 11.00
TRIB's PE(NRI) is ranked higher than
96% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. TRIB: 11.00 )
Ranked among companies with meaningful PE(NRI) only.
TRIB' s 10-Year PE(NRI) Range
Min: 2.08  Med: 16.68 Max: 48.33
Current: 11
2.08
48.33
P/B 0.54
TRIB's P/B is ranked higher than
98% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. TRIB: 0.54 )
Ranked among companies with meaningful P/B only.
TRIB' s 10-Year P/B Range
Min: 0.18  Med: 1.04 Max: 3.49
Current: 0.54
0.18
3.49
P/S 1.55
TRIB's P/S is ranked higher than
74% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. TRIB: 1.55 )
Ranked among companies with meaningful P/S only.
TRIB' s 10-Year P/S Range
Min: 0.16  Med: 1.40 Max: 6.93
Current: 1.55
0.16
6.93
POCF 14.05
TRIB's POCF is ranked higher than
76% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. TRIB: 14.05 )
Ranked among companies with meaningful POCF only.
TRIB' s 10-Year POCF Range
Min: 1.91  Med: 14.08 Max: 83.33
Current: 14.05
1.91
83.33
EV-to-EBIT 20.91
TRIB's EV-to-EBIT is ranked higher than
50% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. TRIB: 20.91 )
Ranked among companies with meaningful EV-to-EBIT only.
TRIB' s 10-Year EV-to-EBIT Range
Min: -1.7  Med: 15.65 Max: 98.5
Current: 20.91
-1.7
98.5
Shiller P/E 11.15
TRIB's Shiller P/E is ranked higher than
96% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. TRIB: 11.15 )
Ranked among companies with meaningful Shiller P/E only.
TRIB' s 10-Year Shiller P/E Range
Min: 2.02  Med: 11.21 Max: 1275
Current: 11.15
2.02
1275
Current Ratio 8.71
TRIB's Current Ratio is ranked higher than
89% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. TRIB: 8.71 )
Ranked among companies with meaningful Current Ratio only.
TRIB' s 10-Year Current Ratio Range
Min: 1  Med: 2.92 Max: 9.17
Current: 8.71
1
9.17
Quick Ratio 6.83
TRIB's Quick Ratio is ranked higher than
85% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. TRIB: 6.83 )
Ranked among companies with meaningful Quick Ratio only.
TRIB' s 10-Year Quick Ratio Range
Min: 0.44  Med: 1.59 Max: 7.6
Current: 6.83
0.44
7.6
Days Inventory 236.73
TRIB's Days Inventory is ranked lower than
95% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. TRIB: 236.73 )
Ranked among companies with meaningful Days Inventory only.
TRIB' s 10-Year Days Inventory Range
Min: 26.55  Med: 215.94 Max: 324.82
Current: 236.73
26.55
324.82
Days Sales Outstanding 100.86
TRIB's Days Sales Outstanding is ranked lower than
80% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. TRIB: 100.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRIB' s 10-Year Days Sales Outstanding Range
Min: 14.75  Med: 67.65 Max: 177.43
Current: 100.86
14.75
177.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.42
TRIB's Dividend Yield is ranked lower than
51% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. TRIB: 1.42 )
Ranked among companies with meaningful Dividend Yield only.
TRIB' s 10-Year Dividend Yield Range
Min: 0.72  Med: 1.01 Max: 1.42
Current: 1.42
0.72
1.42
Dividend Payout 0.33
TRIB's Dividend Payout is ranked higher than
50% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. TRIB: 0.33 )
Ranked among companies with meaningful Dividend Payout only.
TRIB' s 10-Year Dividend Payout Range
Min: 0.3  Med: 0.63 Max: 1.18
Current: 0.33
0.3
1.18
Dividend growth (3y) 30.10
TRIB's Dividend growth (3y) is ranked higher than
86% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. TRIB: 30.10 )
Ranked among companies with meaningful Dividend growth (3y) only.
TRIB' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 30.1
Current: 30.1
0
30.1
Yield on cost (5-Year) 1.43
TRIB's Yield on cost (5-Year) is ranked lower than
56% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. TRIB: 1.43 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TRIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.72  Med: 1.00 Max: 1.44
Current: 1.43
0.72
1.44
Share Buyback Rate -2.20
TRIB's Share Buyback Rate is ranked higher than
60% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.70 vs. TRIB: -2.20 )
Ranked among companies with meaningful Share Buyback Rate only.
TRIB' s 10-Year Share Buyback Rate Range
Min: 26.2  Med: -6.20 Max: -79.2
Current: -2.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.99
TRIB's Price/Net Current Asset Value is ranked higher than
67% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. TRIB: 4.99 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TRIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.61  Med: 3.21 Max: 320
Current: 4.99
0.61
320
Price/Tangible Book 2.11
TRIB's Price/Tangible Book is ranked higher than
77% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. TRIB: 2.11 )
Ranked among companies with meaningful Price/Tangible Book only.
TRIB' s 10-Year Price/Tangible Book Range
Min: 0.4  Med: 2.42 Max: 225
Current: 2.11
0.4
225
Price/Projected FCF 0.80
TRIB's Price/Projected FCF is ranked higher than
94% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. TRIB: 0.80 )
Ranked among companies with meaningful Price/Projected FCF only.
TRIB' s 10-Year Price/Projected FCF Range
Min: 0.28  Med: 1.42 Max: 78.35
Current: 0.8
0.28
78.35
Price/Median PS Value 1.11
TRIB's Price/Median PS Value is ranked lower than
60% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. TRIB: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
TRIB' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 1.15 Max: 5.39
Current: 1.11
0.17
5.39
Price/Graham Number 0.83
TRIB's Price/Graham Number is ranked higher than
95% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. TRIB: 0.83 )
Ranked among companies with meaningful Price/Graham Number only.
TRIB' s 10-Year Price/Graham Number Range
Min: 0.27  Med: 1.00 Max: 11.25
Current: 0.83
0.27
11.25
Earnings Yield (Greenblatt) (%) 4.80
TRIB's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. TRIB: 4.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TRIB' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 5.75 Max: 56.6
Current: 4.8
1
56.6
Forward Rate of Return (Yacktman) (%) -6.25
TRIB's Forward Rate of Return (Yacktman) (%) is ranked lower than
86% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. TRIB: -6.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TRIB' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -31.1  Med: -2.40 Max: 2.5
Current: -6.25
-31.1
2.5

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 101 105
EPS($) 0.48 0.53
EPS without NRI($) 0.48 0.53

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TRBA.Germany,
Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in January 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in the US. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a provider of raw materials to the life sciences industry. The Company markets its portfolio of almost 850 products to customers in approximately 100 countries around the world through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the in-vitro diagnostic market. It also sells raw materials to the life sciences industry. Its Point-of-Care product is Unigold (tm), which tests for the presence of HIV antibodies. It sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its competitors are Abbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK